| 本文已被：浏览 2294次 下载 2018次 |
码上扫一扫！ |
| 东莨菪碱片加东莨菪碱透皮剂与多潘立酮片联合应用对晕船的防治效果 |
| 王俊骎1Δ,潘磊磊1Δ,祁瑞瑞1,江涛2,孙天澜2,周生权2,高忠效2,杨传高2,邵威2,朱政3,蔡懿灵1* |
|
|
(1. 第二军医大学海军医学系航海特殊损伤防护教研室, 上海 200433;
2. 解放军73071部队, 徐州 221400;
3. 上海体育学院运动科学学院, 上海 200438
△共同第一作者
*通信作者) |
|
| 摘要: |
| 目的 观察在不同海况及航渡距离条件下, 东莨菪碱片加东莨菪碱透皮剂与多潘立酮联合应用对晕船的防治效果。 方法 选取236名受试者, 分3批开展试验, 各批试验条件分别为海况1~2级80海里航渡(试验1)、海况3~4级80海里航渡(试验2)及海况3~4级200海里航渡(试验3)。每批受试者均利用晕动症易感性问卷开展易感性评价并根据匹配原则分为3组:综合用药组采用0.3 mg东莨菪碱口服片剂加透皮剂(1.5 mg)与口服多潘立酮片(5 mg)联合应用, 预防用药组仅给予0.3 mg东莨菪碱口服片剂加透皮剂(1.5 mg), 安慰剂对照组则给予维生素C片(100 mg)口服。受试者的晕船严重度采用Wiker量表进行评价。 结果 在试验1中, 综合用药组及预防用药组Wiker评分均低于安慰剂对照组(P<0.05), 两组的中度晕船发生率均低于安慰剂对照组(P<0.05), 而重度晕船发生率各组差异无统计学意义。在试验2中, 综合用药组Wiker评分低于安慰剂对照组(P<0.05);综合用药组和预防用药组重度晕船发生率均低于安慰剂对照组(P<0.05), 而中度晕船发生率各组差异无统计学意义。在试验3中, 综合用药组Wiker评分低于安慰剂对照组(P<0.05), 综合用药组重度晕船发生率低于预防用药组及安慰剂对照组(P<0.05), 而中度晕船发生率各组差异无统计学意义。 结论 小剂量东莨菪碱口服片剂加透皮剂与口服多潘立酮联合应用, 可在较长时间航渡期间缓解晕船症状, 减少重度晕船的发生。 |
| 关键词: 晕动病 东莨菪碱 多潘立酮 |
| DOI：10.16781/j.0258-879x.2016.03.0360 |
| 投稿时间：2015-11-23修订日期：2016-01-19 |
| 基金项目: |
|
| Scopolamine tablet and transdermal agent in combination with domperidone for prevention and treatment of seasickness |
| WANG Jun-qin1Δ,PAN Lei-lei1Δ,QI Rui-rui1,JIANG Tao2,SUN Tan-lan2,ZHOU Sheng-quan2,GAO Zhong-xiao2,YANG Chuan-gao2,SHAO Wei2,ZHU Zheng3,CAI Yi-ling1* |
(1. Department of Nautical Special Injury, Faculty of Navy Medicine, Second Military Medical University, Shanghai 200433, China;
2. No. 73071 Troop of PLA, Xuzhou 221400, Jiangsu, China;
3. School of Kinesiology, Shanghai University of Sports, Shanghai 200438, China
△Co-first authors
* Corresponding author) |
| Abstract: |
| Objective To observe the preventive and therapeutic effects of scopolamine tablet and transdermal agent in combination with domperidone for seasickness in different voyage distances and sea state conditions. Methods A total of 236 participants were selected and batched for three trials (Trial 1: 80 sea miles voyage, 1-2 degree of sea state; Trial 2: 80 sea miles voyage, 3-4 degree of sea state; and Trial 3: 200 sea miles voyage, 3-4 degree of sea state). The motion sickness susceptibility questionnaire (MSSQ) was used to assess the seasickness susceptibility. The participants in each trial were divided into comprehensive medication group (CMG) receiving low dose oral and transdermal scopolamine in combination with oral domperidone, prophylactic medication group (PMG) receiving low dose oral and transdermal scopolamine, and placebo control group (PCG) receiving oral vitamine C. Motion sickness symptoms were evaluated by using Wiker rating scales. Results In trial 1, the Wiker scores and moderate seasickness incidence in the CMG and PMG were significantly lower than those in the PCG (P<0.05). No significant difference was observed in severe seasickness incidence rates among groups (P>0.05). In trial 2, the Wiker scores were significantly lower in the CMG than in the PCG (P<0.05). The incidence rates of severe seasickness were significantly decreased in CMG and PMG compared with PCG (P<0.05). No significant difference was observed in the moderate seasickness incidence rates among 3 groups (P>0.05). In trial 3, the Wiker scores were significantly lower in the CMG than in the PCG (P<0.05). The incidence rates of severe seasickness were significantly reduced in CMG and PMG compared with PCG (P<0.05). No significant difference was observed in the moderate seasickness incidence rates among 3 groups (P>0.05). Conclusion Low dose oral and transdermal scopolamine in combination with oral domperidone can alleviate seasickness symptoms and decrease incidence of severe seasickness during long-term voyage at sea. |
| Key words: motion sickness scopolamine domperidone |
